Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Total Assets : $229.43 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Lexicon Pharmaceuticals Total Assets?

Lexicon Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $229.43 Mil.

During the past 12 months, Lexicon Pharmaceuticals's average Total Assets Growth Rate was 6.20% per year. During the past 3 years, the average Total Assets Growth Rate was 4.90% per year. During the past 5 years, the average Total Assets Growth Rate was -17.20% per year. During the past 10 years, the average Total Assets Growth Rate was -10.70% per year.

During the past 13 years, Lexicon Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 115.50%. The lowest was -27.40%. And the median was -1.90%.

Total Assets is connected with ROA %. Lexicon Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was -78.68%. Total Assets is also linked to Revenue through Asset Turnover. Lexicon Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Lexicon Pharmaceuticals Total Assets Historical Data

The historical data trend for Lexicon Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals Total Assets Chart

Lexicon Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

417.72

203.79

136.91

194.30

229.43

Lexicon Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															194.30	162.72	316.72	276.48	229.43

Lexicon Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Lexicon Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	93.11	+	136.319
	=	229.43

Lexicon Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	93.11	+	136.319
	=	229.43

Lexicon Pharmaceuticals (NAS:LXRX) Total Assets Explanation

Total Assets is connected with ROA %.

Lexicon Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-199.024	/	( (276.479	+	229.429)	/ 2 )
	=	-199.024	/	252.954
	=	-78.68 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Lexicon Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0.702	/	( (276.479	+	229.429)	/ 2 )
=	0.702	/	252.954
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Lexicon Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (NAS:LXRX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381

Website

https://www.lexpharma.com

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Executives

Philippe Amouyal	director	C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016
Lonnel Coats	director, officer: President and CEO	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Raymond Debbane	director, 10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022
Thomas Garner	officer: SVP, Chief Commercial Officer	2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381
Jeffrey L Wade	officer: EVP, Gen. Counsel	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Wendy Mcdermott	officer: VP, Human Resources	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Diane E. Sullivan	director	C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Artal International S.c.a.	director, 10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Invus Partners, Llc	director, 10 percent owner	750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022
Ulys, Llc	director, 10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Kiernan Seth	officer: VP, Chief Commercial Officer	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kenneth B. Kassler-taub	officer: SVP, Regulatory & QA	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kristen Alexander	officer: VP, Finance and Accounting	2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Craig B Granowitz	officer: SVP, Chief Medical Officer	58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960
James F Tessmer	officer: VP, Finance & Acctg	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381